Brain tumor patients may skip radiation without harming survival

NCT ID NCT02444000

Completed Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jan 26, 2026 · Last updated Jun 23, 2026 · Updated 22 times

Summary

This study tested whether using chemotherapy alone could delay or avoid radiotherapy in people with a specific genetic type of brain tumor (1p/19q codeleted anaplastic glioma). The goal was to see if skipping radiation helps preserve thinking and memory without shortening survival. 280 newly diagnosed adults were randomly assigned to receive either PCV chemotherapy alone or radiotherapy followed by PCV chemotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC GLIOMAS WITH 1P/19Q CODELETION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

CH Louis Pasteur

Colmar, 68000, France
CHU Bretonneau

Tours, 37000, France
CHU D'Anger

Angers, 49000, France
CHU Sud Réunion

La Réunion, 97000, France
CHU annecy genevois

Annecy, 74000, France
CHU d'Amiens- CHU nord

Amiens, 80000, France
CHU de Bordaux

Bordeaux, 33000, France
CHU de Caen

Caen, 30000, France
CHU de Poitiers

Poitiers, 86000, France
CHU de Rouen

Rouen, 76000, France
CHU la Timone

Marseille, 13000, France
CLCC Eugène Marquis

Rennes, 44000, France
CLCC Institut Gustave Roussy

Villejuif, 94800, France
Centre Hospitalier Perpignan

Perpignan, 49000, France
Centre Hospitalier de Bretagne Sud - Hôpital du Scorff

Lorient, 56000, France
Chu Dupuytren

Limoges, 87000, France
GH Est-Institut d'hématologie et d'oncologie pédiatrique IHOP

Lyon, 69000, France
Groupe Hospitalier Pitié Salpetriere

Paris, 75013, France
HIA du Val de Grâce

Paris, 75005, France
Hopital CLAIRVAL

Marseille, 13000, France
Hopital François Mitterand

Dijon, 21000, France
Hopital Gabriel Montpied

Clermont-Ferrand, 63000, France
Hopital PASTEUR

Nice, 06000, France
Hopital Roger Salengro

Lille, 59000, France
Hopital Saint Louis

Paris, 75010, France
Hopital de la Cavale Blanche

Brest, 29000, France
Hôpital Foch

Suresnes, 92000, France
Hôpital Nord, CHU de Saint-Etienne

Saint-Etienne, 42000, France
Hôpital Pierre Wertheimer

Lyon, 69000, France
ICM, Institut régional du Cancer de Montpellier

Montpellier, 34000, France
IUCT Oncopole - CLCC Institut Claudius Regaud

Toulouse, 31000, France
Institut Pul STRAUSS

Strasbourg, 67000, France
Institut de Cancérologie de l'Ouest (ICO) - site CLCC René Gauducheau

Nantes, 44000, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

PCV chemotherapy (CCNU, vincristine, procarbazine)

What this could lead to

If successful, this could show that chemotherapy alone is as effective as chemo plus radiotherapy for these brain tumors, while reducing the risk of cognitive decline.

What could go wrong

This is a completed Phase 3 trial, but results may not apply to all patients. Chemotherapy alone might still lead to tumor progression or side effects like nerve damage or low blood counts.

Conditions

The condition(s) this trial relates to.

IDH-mutant and 1p/19q-codeleted oligodendroglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC GLIOMAS WITH 1P/19Q CODELETION